Pentostatin, Cyclophosphamide and Rituximab Followed by Alemtuzumab for Relapsed or Refractory Chronic Lymphocytic Leukemia: A Phase 2 Trial of the ECOG-ACRIN Cancer Research Group (E2903)

Patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) may benefit from salvage chemoimmunotherapy (CIT). To explore further the use of CIT in the pre-novel agent era, ECOG-ACRIN undertook a phase 2 trial (E2903) for R/R CLL utilizing pentostatin, cyclophosphamide, and rituximab...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Acta Haematol
Main Authors: Kempin, Sanford, Sun, Zhuoxin, Kay, Neil E., Paietta, Elisabeth M., Mazza, Joseph J., Ketterling, Rhett P., Frankfurt, Olga, Claxton, David F., Saltzman, Joel N., Srkalovic, Gordan, Callander, Natalie S., Gross, Gerald, Tallman, Martin S
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6834875/
https://ncbi.nlm.nih.gov/pubmed/31336367
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000500164
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados